PFD Week Abstracts Show Leva’s Long-Term Treatment Value for Female Urinary Incontinence Plus New Data for Other Pelvic Floor Disorders

AUGS PFD Week 2023— Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, commends leading researchers in women’s health, who presented data showing that urinary incontinence (UI) symptom relief is durable for two-years following eight-weeks of treatment with the Leva® Pelvic Health System. These researchers also presented data showing that the Leva System improved symptoms of early-stage pelvic organ prolapse, a pelvic floor disorder in which one or more of the pelvic organs drop or press into or out of the vagina due to a weak pelvic floor. The Leva System is a non-drug, non-surgical treatment that helps women strengthen their pelvic floor at home, on their own schedule, by guiding correct and consistent pelvic floor muscle training (PFMT). The researchers presented their data in two abstracts during PFD Week 2023, the American Urogynecologic Society’s (AUGS) annual scientific meeting held in Portland, Ore. Oct. 4-6, 2023.

The abstract, “Digital Therapeutic Device for Urinary Incontinence: An 18- and 24-month Follow-up of a Randomized Controlled Trial,” showed that the Leva System provided durable and significantly greater improvement in stress and mixed UI symptoms compared to a home-based program of PFMT alone, regardless of whether women continued Leva use beyond the eight-week treatment period. The authors, who are widely recognized for their expertise in women’s pelvic floor health, include Milena M. Weinstein, MD of Massachusetts General Hospital, Harvard Medical School, Gena Dunivan, MD of the University of Alabama, Noelani Guaderrama, MD of Kaiser Southern California and Holly E. Richter, PhD, MD of the University of Alabama. The abstract is significant for several reasons:

  • It provides long-term evidence for a non-surgical UI intervention, contributing to overall knowledge of how women can achieve durable symptom relief from what is often a long-term, progressive condition.
  • It extends the findings of a randomized controlled superiority trial (RCT), published in Obstetrics and Gynecology (The Green Journal) in 2022, which showed the Leva Systemwas statistically and clinically superior to Kegel exercises alone for stress and mixed UI symptom improvement and a prior longitudinal analysis showing that these improvements last 12 months, even without ongoing use of the Leva System. The Green Journal published the 12-month longitudinal analysis in January 2023.
  • The authors conclude that for women choosing first-line, at-home care for stress or mixed UI, a motion-based device should be considered to optimize results.

“It’s both exemplary and rare for a medical device that treats UI to have two-year longitudinal follow up to a randomized controlled trial,” said Samantha Pulliam, chief medical officer for Axena Health. “We do, and it provides powerful validation of the Leva Pelvic Health System’s treatment value for women. Now, data show UI symptom relief lasts for 24 months. We remain exceedingly grateful to the researchers who are building a compendium of data that support women’s access to drug-free, surgery-free treatment for urinary incontinence that reflects conservative, first-line treatment guidelines.”

Updated prevalence data show 61.8 percent of adult women live with UI, a progressive condition that can negatively impact women’s quality of life and impose enormous physical, psychological, and economic burdens. Clinical guidelines recommend PFMT, as first-line treatment for UI, but achieving effective, consistent results is challenging. The Leva System makes PFMT accessible by guiding women through their treatment. The U.S. Food and Drug Administration (FDA) cleared the Leva System in 2019 for the treatment of stress, mixed and mild-to-moderate urgency UI. On June 20, 2023, Axena Health introduced the Leva System for the treatment of chronic fecal incontinence in women following FDA clearance in 2022 and Breakthrough Device Designation in 2021. The new product introduction supports a single treatment option for the 20 percent of women with both UI and FI.

“Drs. Weinstein, Dunivan, Guaderrama and Richter are among the most respected clinician-researchers in their field, and they’ve amassed the highest quality evidence supporting the treatment value of the Leva Pelvic Health System,” said Axena Health CEO Eileen Maus. “With more than half of adult women living with urinary incontinence, the quality of data supporting Leva’s effectiveness and strong clinician demand for better treatment options, it’s now egregious for insurance companies to deny coverage. Incontinence for many is a progressive condition that leads to adult diapers and older women entering nursing homes prematurely. Leva makes FDA-cleared, clinically proven, first-line treatment for incontinence accessible.”

In the abstract, “Impact of pelvic floor muscle training with and without a motion-based device on pelvic floor disorder symptoms,” the authors analyzed the data from the original UI RCT to evaluate PFMT’s impact on symptoms of fecal incontinence (FI) and pelvic organ prolapse (POP). The analysis shows that PMFT treatment with the Leva System resulted in FI and POP symptom improvement. The research also showed that women with multiple pelvic floor disorders had more severe UI symptoms than women with UI only. The Leva System is not FDA cleared for the treatment of POP.

Source link :

Newsletter Updates

Enter your email address below and subscribe to our newsletter